Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

Életkor

• Patient must not be enrolled if he/she fulfils one of the following non-inclusion criteria:
  • <18 years old at diagnosis.
  • Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria.
  • Tumor sample not available or not reaching the required quality for multi-omic analyses.

• FOR SURVIVORS
• To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:
  • Adult patient (≥18 years old at diagnosis).
  • Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.
  • Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt.
  • Availability of at least one block sample and associated clinical annotations with following characteristics:
  • One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual
  • Any treatment prior to sample acquisition must be reported - all treatments accepted (standard / targeted);
  • Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM
  • For CONTROL GROUPS :
• To be eligible the control patients must fulfill the following inclusion criteria:
  • ≥18 years old at diagnosis.
  • Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer.
  • Paired to long-term survivors as mentioned in the methodology section
  • Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease
  • Availability of at least one tumor sample and associated clinical annotations with following characteristics:
  • Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses
  • Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard / targeted).